URL
https://www.clinicaltrials.gov/ct2/show/NCT03971409?term=NCT03971409&draw=2&rank=1

Baylor, Dana-Farber/ Harvard Cancer Center, Duke, Georgetown University, Johns Hopkins University, Mayo Clinic Cancer Center, Montefiore Medical Center, University of Alabama at Birmingham Comprehensive Cancer Center, University of California San Francisco, University of Chicago Medical Center, University of North Carolina at Chapel Hill, University of Pennsylvania, Vanderbilt University

Long title
Avelumab with Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Patients with Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer (InCITe)